+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Factor IX"

From
From
From
Hemophilia Drugs - Global Strategic Business Report - Product Thumbnail Image

Hemophilia Drugs - Global Strategic Business Report

  • Report
  • April 2025
  • 182 Pages
  • Global
From
Acquired Hemophilia Treatment Market Report 2025 - Product Thumbnail Image

Acquired Hemophilia Treatment Market Report 2025

  • Report
  • March 2025
  • 200 Pages
  • Global
From
From
From
Hemophilia B - Pipeline Insight, 2024 - Product Thumbnail Image

Hemophilia B - Pipeline Insight, 2024

  • Clinical Trials
  • May 2024
  • 80 Pages
  • Global
From
From
From
From
From
From
Loading Indicator

Factor IX is a protein used to treat hemophilia B, a rare genetic disorder that impairs the body's ability to form blood clots. It is a recombinant form of the human factor IX protein, which is produced in a laboratory setting. Factor IX is administered intravenously or subcutaneously to replace the missing clotting factor in patients with hemophilia B. It is used to prevent and treat bleeding episodes, as well as to prevent bleeding during surgery. Factor IX is a part of the larger hematological drugs market, which includes drugs used to treat blood-related diseases and disorders. These drugs are used to treat a wide range of conditions, including anemia, leukemia, and thrombocytopenia. Some companies in the Factor IX market include Novo Nordisk, Pfizer, Bayer, and Biogen. Show Less Read more